These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 30850252)
21. Clostridium difficile and fluoroquinolones: is there a link? Weiss K Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S29-32. PubMed ID: 19303566 [TBL] [Abstract][Full Text] [Related]
22. Antimicrobial Stewardship and the Infection Control Practitioner: A Natural Alliance. Zhou S; Nagel JL; Kaye KS; LaPlante KL; Albin OR; Pogue JM Infect Dis Clin North Am; 2021 Sep; 35(3):771-787. PubMed ID: 34362543 [TBL] [Abstract][Full Text] [Related]
23. PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates. Solomon K; Fanning S; McDermott S; Murray S; Scott L; Martin A; Skally M; Burns K; Kuijper E; Fitzpatrick F; Fenelon L; Kyne L J Antimicrob Chemother; 2011 Sep; 66(9):1976-82. PubMed ID: 21712239 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of a stewardship intervention focused on reducing unnecessary use of non- Hecker MT; Son AH; Alhmidi H; Wilson BM; Wiest PM; Donskey CJ Infect Control Hosp Epidemiol; 2020 Feb; 41(2):216-218. PubMed ID: 31843033 [TBL] [Abstract][Full Text] [Related]
25. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use]. Jónsdóttir K; Kristinsson KG Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726 [TBL] [Abstract][Full Text] [Related]
26. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290 [TBL] [Abstract][Full Text] [Related]
28. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis. Nyc O; Tejkalova R; Kriz Z; Ruzicka F; Kubicek L; Matejkova J; Kuijper E; Krutova M Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531 [TBL] [Abstract][Full Text] [Related]
29. A Multifaceted Antimicrobial Stewardship Program for the Treatment of Uncomplicated Cystitis in Nursing Home Residents. Nace DA; Hanlon JT; Crnich CJ; Drinka PJ; Schweon SJ; Anderson G; Perera S JAMA Intern Med; 2020 Jul; 180(7):944-951. PubMed ID: 32391862 [TBL] [Abstract][Full Text] [Related]
30. Stepwise Expansion of Antimicrobial Stewardship Programs and Its Impact on Antibiotic Use and Resistance Rates at a Tertiary Care Hospital in Korea. Shin DH; Kim HS; Heo E; Shin MJ; Kim NH; Lee H; Park JS; Park KU; Jung J; Song KH; Kang M; Jung J; Kim ES; Kim HB Microbiol Spectr; 2022 Jun; 10(3):e0033522. PubMed ID: 35467411 [TBL] [Abstract][Full Text] [Related]
31. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Wong-Beringer A; Nguyen LH; Lee M; Shriner KA; Pallares J Pharmacotherapy; 2009 Jun; 29(6):736-43. PubMed ID: 19476424 [TBL] [Abstract][Full Text] [Related]
32. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. Aldeyab MA; Kearney MP; Scott MG; Aldiab MA; Alahmadi YM; Darwish Elhajji FW; Magee FA; McElnay JC J Antimicrob Chemother; 2012 Dec; 67(12):2988-96. PubMed ID: 22899806 [TBL] [Abstract][Full Text] [Related]
33. Antimicrobial stewardship program achieved marked decrease in Clostridium difficile infections in a Veterans Hospital. Morgan F; Belal M; Lisa B; Ford F; LeMaitre B; Psevdos G Am J Infect Control; 2020 Sep; 48(9):1119-1121. PubMed ID: 32035688 [TBL] [Abstract][Full Text] [Related]
34. Impact of an Antimicrobial Stewardship Program on Resistance to Fluoroquinolones of Urinary Enterobacteriaceae Isolated From Nursing Home Residents: A Retrospective Cohort Study. Strazzulla A; Bokobza S; Ombandza E; Kherallah K; Hommel S; Draidi R; Bonutto C; Zamponi DB; Gauzit R; Diamantis S J Am Med Dir Assoc; 2020 Sep; 21(9):1322-1326. PubMed ID: 32199718 [TBL] [Abstract][Full Text] [Related]
35. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240 [TBL] [Abstract][Full Text] [Related]
37. Impact of intensive infection control team activities on the acquisition of methicillin-resistant Staphylococcus aureus, drug-resistant Pseudomonas aeruginosa and the incidence of Clostridium difficile-associated disease. Suzuki H; Senda J; Yamashita K; Tokuda Y; Kanesaka Y; Kotaki N; Ishihara H; Ishikawa H J Infect Chemother; 2013 Dec; 19(6):1047-52. PubMed ID: 23715827 [TBL] [Abstract][Full Text] [Related]
38. Short- and long-term impact of a multifaceted approach targeting fluoroquinolone use in a community hospital: an interrupted time-series analysis. Belsky B; Minson Q Int J Clin Pharm; 2022 Jun; 44(3):741-748. PubMed ID: 35451671 [TBL] [Abstract][Full Text] [Related]